In a report released today, Daniel Arias from Stifel Nicolaus maintained a Hold rating on AbSci (ABSI – Research Report), with a price ...

Good day and thank you for standing by. Welcome to the Absci Q3 2024 Business Update Conference Call. At this time, all ...

Absci Corp. ( (ABSI) ) has released its Q3 earnings. Here is a breakdown of the information Absci Corp. presented to its investors. Absci ...

On the heels of releasing its latest financial statement, Vancouver-based biotechnology company Absci announced it has met its first milestone in its collaboration with pharmaceutical giant AstraZenec ...

Absci Corporation (ABSI) came out with a quarterly loss of $0.24 per share versus the Zacks Consensus Estimate of a loss of $0.19. This compares to loss of $0.24 per share a year ago. These figures ...

Absci Corp (ABSI) showcases promising collaborations and a robust pipeline amid rising R&D expenses and revenue challenges.

DNA synthesis platform developer joins de novo designer in latest of three partnerships recently launched or advanced.

Absci's differentiated drug discovery platform could create significant shareholder value long term. The company has a long and expensive path to traverse before it can prove the merits of its ...

Absci Corp (NASDAQ:ABSI) is set to release its Q3 2024 earnings on Nov 12, 2024. The consensus estimate for Q3 2024 revenue is $1.75 million, and the earnings are expected to come in at -$0.20 per ...

Good day, and thank you for standing by. Welcome to the Absci Q3 2024 business update conference call. (Operator Instructions) Please be advised that today's conference is being recorded. I would now ...